Skip to main content

Table 3 Neuromotor developmental milestones (ITTE population)

From: Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at < 4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial

Characteristics Visit Statistics ‘sapropterin continuous’ (n = 25) ‘sapropterin extension’ (n = 26)
Area of assessment fine motor skills, n (%) Baseline Normal 16 (69.6) 24 (92.3)
  Abnormal 7 (30.4) 2 (7.7)
Month 12 Normal 16 (69.6) 22 (91.7)
  Abnormal 7 (30.4) 2 (8.3)
Month 24 Normal 16 (94.1) 16 (88.9)
  Abnormal 1 (5.9) 2 (11.1)
EOS Normal 11 (84.6) 14 (100.0)
  Abnormal 2 (15.4) 0
Area of assessment gross motor skills, n (%) Baseline Normal 21 (91.3) 19 (73.1)
  Abnormal 2 (8.7) 7 (26.9)
Month 12 Normal 21 (91.3) 22 (91.7)
  Abnormal 2 (8.7) 2 (8.3)
Month 24 Normal 14 (82.4) 15 (83.3)
  Abnormal 3 (17.6) 3 (16.7)
EOS Normal 12 (92.3) 14 (100.0)
  Abnormal 1 (7.7) 0
Area of assessment language, n (%) Baseline Normal 20 (87.0) 22 (84.6)
  Abnormal 3 (13.0) 4 (15.4)
Month 12 Normal 18 (78.3) 21 (87.5)
  Abnormal 5 (21.7) 3 (12.5)
Month 24 Normal 14 (82.4) 14 (77.8)
  Abnormal 3 (17.6) 4 (22.2)
EOS Normal 12 (92.3) 11 (78.6)
  Abnormal 1 (7.7) 3 (21.4)
Area of assessment personal-social, n (%) Baseline Normal 20 (87.0) 20 (76.9)
  Abnormal 3 (13.0) 6 (23.1)
Month 12 Normal 21 (91.3) 19 (79.2)
  Abnormal 2 (8.7) 5 (20.8)
Month 24 Normal 16 (94.1) 14 (77.8)
  Abnormal 1 (5.9) 4 (22.2)
EOS Normal 13 (100.0) 14 (100.0)
  Abnormal 0 0
  1. EOS end of extension period (month 36), ITTE intention-to-treat extension (population)